PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadobutrol→

Gadobutrol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
770691-21-9
Molecular formula
C18H31GdN4O9
Molecular weight
604.7 g/mol
Drug class
Gadolinium-based MRI contrast agentmacrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact macrocyclic gadolinium chelate is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic chelate, not a therapeutic agent.
Indications / reported uses
  • Contrast enhancement for MRI of the central nervous system and other body regions in adults and paediatric patients, including neonates, with known or suspected abnormalities; exact age, organ and dose indications follow the product label

Sources: US DailyMed — GADAVIST (gadobutrol) · EMA EPAR — Gadovist · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gadobutrol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadobutrol Permitted Daily Exposure (PDE) report (the Gadobutrol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadobutrol Occupational Exposure Limit (OEL) report (the Gadobutrol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.